Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis

PHASE3CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

March 21, 2024

Study Completion Date

March 21, 2024

Conditions
Plantar Fibromatosis
Interventions
BIOLOGICAL

EN3835

Treatment or retreatment with EN3835

Trial Locations (27)

17402

Endo Clinical Trial Site #9, York

19331

Endo Clinical Trial Site #12, Bakersfield

21122

Endo Clinical Trial Site #6, Pasadena

23434

Endo Clinical Trial Site #20, Suffolk

30043

Endo Clinical Trial Site #22, Lawrenceville

33172

Endo Clinical Trial Site #21, Sweetwater

33176

Endo Clinical Trial Site #24, Miami

33782

Endo Clinical Trial Site #8, Pinellas Park

62269

Endo Clinical Trial Site #2, O'Fallon

62521

Endo Clinical Trial Site #19, Decatur

62704

Endo Clinical Trial Site #14, Springfield

65109

Endo Clinical Trial Site #16, Jefferson City

75208

Endo Clinical Trial Site #17, Dallas

75251

Endo Clinical Trial Site #26, Dallas

76021

Endo Clinical Trial Site #4, Bedford

76104

Endo Clinical Trial Site #5, Fort Worth

77027

Endo Clinical Trial Site #7, Houston

77095

Endo Clinical Trial Site #10, Houston

78501

Endo Clinical Trial Site #1, McAllen

78628

Endo Clinical Trial Site #27, Georgetown

83642

Endo Clinical Trial Site #25, Meridian

84107

Endo Clinical Trial Site #11, Salt Lake City

90603

Endo Clinical Trial Site #18, Whittier

91356

Endo Clinical Trial Site #13, Tarzana

91942

Endo Clinical Trial Site #23, La Mesa

92083

Endo Clinical Trial Site #15, Vista

93710

Endo Clinical Trial Site #3, Fresno

Sponsors
All Listed Sponsors
lead

Endo Pharmaceuticals

INDUSTRY